www.fdanews.com/articles/138420-biomarin-initiates-phase-i-trial-for-bmn-673-in-patients-with-advanced-hematological-malignancies

BioMarin Initiates Phase I Trial for BMN 673 in Patients With Advanced Hematological Malignancies

July 15, 2011

BioMarin Pharmaceutical announced the initiation of a Phase I trial for BMN 673, a poly ADP-ribose polymerase (PARP) inhibitor, for the treatment of patients with advanced hematological malignancies.
MarketWatch